Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients hospitalized due to decompensated heart failure who require IV inotropic and/or vasodilator and diuretic therapy~2. Patients receiving appropriate medical therapy for heart failure, defined as ACE inhibitors and beta blockers (all unless not tolerated or contraindicated) and diuretics, for 1 month prior to study entry~3. For at least 24 hours prior to inclusion into the study, the patient should be treated with a minimum dose of the following: dobutamine 2.5μg/kg/min or milrinone 0.3μg/kg/min or dopamine 5μg/kg/min. or nesiritide 0.01μg/kg/min or nitroglycerin 0.3 µg/kg/min or nitroprusside 0.3 µg/kg/min or a combination of any of these agents, with diuretic therapy. Doses of the above stated medications should be stable for 6 hours prior to inclusion into study. An increase in this dosage within the first 8 hours after enrollment is determined by the attending physician to be unlikely and the following definition of not responding adequately to IV inotropic and/or vasodilator and diuretic therapy is exhibited:~   * PCWP is ≥ 20 mmHg at time of randomization and PCWP was ≥ 18 mmHg continuously for 24 hours or PCWP ≥ 20 mmHg continuously for 12 hours prior to randomization.~  * Cardiac Index \< 2.4 L/min/m2~  * There is evidence for abnormal renal function and/or diuretic resistance defined as: Serum creatinine \> 1.2 mg/dL or Diuretic dosage of intravenous Furosemide ≥ 120 mg daily, or equivalent~4. LVEF \< 35%~5. Male or female 18-90 years of age~6. If female, no child-bearing potential or negative pregnancy test~7. Written informed consent~8. Willingness to participate in required follow-up exams~Exclusion Criteria:~1. Acute Q-wave myocardial infarction within past 7 days~2. Post cardiotomy shock within past 30 days~3. Cardiac surgery within past 14 days~4. Bridge to transplant~5. History of severe COPD as defined as FEV1 \< 1.0 liter~6. History of malignant arrhythmias defined as either:~   * sustained ventricular tachycardia \> 15 beats or more in length, not associated with a correctable cause, within the preceding 3 months, unless the patient presently has an implantable cardiac defibrillator.~  * history of ventricular fibrillation or sudden death, unless the patient presently has an implantable cardiac defibrillator~7. Patients implanted with a resynchronization device within the previous 14 days or if there is a possibility of implant within 60 days following randomization~8. Systolic pressure \<80 mmHg~9. Requiring cardiopulmonary support type devices~10. Platelets \< 50,000/mm3 or other evidence of coagulopathy, INR greater than 1.5 in the absence of anticoagulation therapy.~11. Infection (WBC ≥ 12.5 x 103/ml, and or temperature ≥ 100.5°F/38°C)~12. History of cerebral vascular accident (CVA) or transient ischemic attacks (TIA) within the last 3 months~13. Unwilling or unable to receive blood transfusion~14. Inability to undergo treatment with heparin~15. Patients on dialysis or serum creatinine \> 4.0 mg/dl~16. Primary liver disease with bilirubin, SGOT, or SGPT \> 4X upper limit of normal~17. Life expectancy from other disease \< 12 months~18. Patients who are active on the cardiac transplantation waiting list, unless there is a documented reason (large body habitus, highly sensitized, O blood group) to anticipate that transplant is unlikely within the subsequent 65 days.~19. Symptomatic patent foramen ovale or intracardiac shunt~20. Patients diagnosed with clinically significant peripheral vascular disease, defined as absent pedal pulse or signs or symptoms of limb ischemia, including a history of intermittent claudication~21. Patients with amyloidosis, thyroid induced heart failure, high output failure secondary to an arterio-venous fistula, and significant uncorrected primary valvular disease (with the exception of mitral regurgitation believed secondary to LV dilatation)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy